Hong Kong stock movement: MicroPort Medbot-B surged 20.09%, boosted by new product approvals and a surge in orders, enhancing market confidence

Hong Kong Stock Movement MircroPort Medbot-B surged 20.09%. Based on recent key news: On December 29, MircroPort Medbot-B's independently developed bronchoscopic surgical robot, the UniPath electronic bronchoscope surgical navigation system, received approval from the National Medical Products Administration. The approval of this product enhances the company's competitiveness in the surgical robot field, driving the stock price up. On December 28, MircroPort Medbot-B announced that the cumulative order volume of its core products in endoscopy, orthopedics, and vascular intervention has exceeded 230 units, with the global order volume of the Tumai endoscopic surgical robot ranking among the top two globally. This indicates strong market demand for its products, further supporting the rise in stock price. On December 28, MircroPort Medbot-B announced that the number of its approved products in the surgical robot field has increased to 7, making it the first company globally to commercialize products in five major golden track categories. This achievement has boosted market confidence in the company, propelling the stock price upward. The demand in the surgical robot industry is strong, and market confidence is increasing. Stocks with High Trading Volume in the Industry MircroPort Medical rose 3.39%, with a trading volume of HKD 110 million, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. MircroPort Neuroscience rose 3.29%, with a trading volume of HKD 18.2 million, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. Xianjian Technology had a trading volume of HKD 7.63 million. Based on recent news: On December 26, in terms of international expansion, the focus is on product development and sales progress in the European and American markets. Due to previous layouts of many companies in overseas channel mergers and production bases, the overseas market growth of the sector is expected to accelerate by 2026. This news has boosted market confidence, driving up Xianjian Technology's stock price. On December 26, low-value consumable companies are accelerating their layout of overseas production bases to restore and expand their competitiveness in the U.S. market. After the production of overseas bases by leading companies in 2026, they are expected to quickly regain the U.S. market share lost due to tariff policies, achieving clear profit increments. This positive expectation further propelled Xianjian Technology's stock price upward. On December 26, the centralized procurement of major in vitro diagnostic products has been implemented and is gradually being carried out. Although the overall market scale has been compressed, domestic leading companies are continuously increasing their market share due to price and channel advantages, accelerating import substitution. The price impact brought by centralized procurement and the policy suppression on testing volume will gradually fade, and the overall testing demand in the industry will still recover due to the aging trend and the increase in residents' testing penetration rate. This news has had a positive impact on Xianjian Technology. The overall industry performance is good, and international expansion is accelerating. Stocks with High Market Capitalization in the Industry Angelalign fell 0.49%. Based on recent key news: On December 26, Angelalign held an MDR-CE certificate awarding ceremony in Shanghai. This event marks an important progress for the company in compliance and international certification in the medical device field, enhancing market confidence in its future development. However, the stock price still experienced a slight decline, which may reflect the market's cautious attitude towards short-term performance. Source: Company official WeChat account. The medical device industry has recently experienced significant fluctuations